Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study von Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.

Volltext

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma von Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M.C., Niederle, B., Cohen, E.E.W., Wirth, L., Ali, H., Clary, D.O., Yaron, Y., Mangeshkar, M., Ball, D., Nelkin, B., Sherman, S.

Volltext

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial von Smallridge, R. C, Copland, J. A, Brose, M. S, Wadsworth, J. T, Houvras, Y, Menefee, M. E, Bible, K. C, Shah, M. H, Gramza, A. W, Klopper, J. P, Marlow, L. A, Heckman, M. G, Von Roemeling, R

Volltext

Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines von Damek-Poprawa, M., Volgina, A., Korostoff, J., Sollecito, T.P., Brose, M.S., O’Malley, B.W., Akintoye, S.O., DiRienzo, J.M.

Volltext

Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus von Wouters, E. F. M, Bredenbröker, D, Teichmann, P, Brose, M, Rabe, K. F, Fabbri, L. M, Göke, B

Volltext

The intentional pursuit of everyday life while dying: A longitudinal qualitative study of working-aged adults living with advanced cancer von Brose, Julie M, Willis, Eileen, Morgan, Deidre D

Volltext

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK von Neely, R J, Brose, M S, Gray, C M, McCorkell, K A, Leibowitz, J M, Ma, C, Rothstein, J L, May, M J

Volltext

Renal scintigraphy as an early and efficient method for detecting loss of renal function in a cat von Schaefer, Gabriela C, Brose, Mariana M, Becerra, José R Herrera, Mello, Fabíola PS, Rovaris, Inácio B, Herz Berdichevski, Eduardo, Ferreira, Márcio P, da Costa, Fernanda VA

Volltext

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer von Hadoux, Julien, Elisei, Rossella, Brose, Marcia S., Hoff, Ana O., Robinson, Bruce G., Gao, Ming, Jarzab, Barbara, Isaev, Pavel, Kopeckova, Katerina, Wadsley, Jonathan, Führer, Dagmar, Keam, Bhumsuk, Bardet, Stéphane, Sherman, Eric J., Tahara, Makoto, Hu, Mimi I., Singh, Ravinder, Lin, Yan, Soldatenkova, Victoria, Wright, Jennifer, Lin, Boris, Maeda, Patricia, Capdevila, Jaume, Wirth, Lori J.

Volltext

Determination of atomic and molecular particle densities and temperatures in a low-pressure hydrogen hollow cathode discharge von Biel, W, Bröse, M, David, M, Kempkens, H, Uhlenbusch, J

Volltext

Functional, work-related rehabilitative programming for cancer survivors experiencing cancer-related fatigue von Dolgoy, Naomi, Brose, Julie M, Dao, Thao, Suderman, Kirsten, Gross, Douglas P, Ho, Chester, Culos-Reed, S Nicole, McNeely, Margaret L

Volltext

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial von Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M., Hurria, A.

Volltext

Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the phase 3 DECISION trial von Kappeler, C., Meinhardt, G., Elisei, R., Brose, M., Schlumberger, M.

Volltext

A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung von Gombos, Z, Danihel, L, Puttaswamy, K, Brose, M

Volltext

Roflumilast with long-acting β 2 -agonists for COPD: influence of exacerbation history von Bateman, E.D., Rabe, K.F., Calverley, P.M.A., Goehring, U.M., Brose, M., Bredenbröker, D., Fabbri, L.M.

Volltext

Cancer-associated thrombosis: prevention and treatment von Brose, K M J, Lee, A Y Y

Volltext

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial von Makker, V., Rasco, D., Vogelzang, N., Brose, M., Cohn, A., Mier, J., DiSimone, C., Hyman, D.M., Stepan, D., Dutcus, C., Schmidt, E., Guo, M., Sachdev, P., Shumaker, R., Aghajanian, C., Taylor, M.

Volltext

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology von Masters, Gregory A, Krilov, Lada, Bailey, Howard H, Brose, Marcia S, Burstein, Harold, Diller, Lisa R, Dizon, Don S, Fine, Howard A, Kalemkerian, Gregory P, Moasser, Mark, Neuss, Michael N, O'Day, Steven J, Odenike, Olatoyosi, Ryan, Charles J, Schilsky, Richard L, Schwartz, Gary K, Venook, Alan P, Wong, Sandra L, Patel, Jyoti D

Volltext

Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы... von Tahara, M., Brose, M. S., Wirth, L. J., Suzuki, T., Miyagishi, H., Fujino, K., Dutcus, C. E., Gianoukakis, A.

Volltext

Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the... von Brose, M., Jarzab, B., Elisei, R., Giannetta, L., Bastholt, L., Fouchardiere, Cdela, Pacini, F., Paschke, R., Nutting, C., Shong, Y.K., Sherman, S., Smit, J., Chung, J., Meinhardt, G., Schlumberger, M., Kappeler, C.

Volltext